Are endocrine disruptors among the causes of the deterioration of aquatic biodiversity?
✍ Scribed by Jin Zhou; Zhong-Hua Cai; Xiao-Shan Zhu
- Book ID
- 102275465
- Publisher
- Society of Environmental Toxicology and Chemistry
- Year
- 2010
- Tongue
- English
- Weight
- 116 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1551-3777
- DOI
- 10.1002/ieam.47
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Exposure to environmental pollutants such as endocrine‐disrupting compounds (EDCs) is now taken into account to explain partially the biodiversity decline of aquatic ecosystems. Much research has demonstrated that EDCs can adversely affect the endocrine system, reproductive health, and immune function in aquatic species. These toxicological effects include 1) interference with normal hormonal synthesis, release, and transport, 2) impairment of growth, development, and gonadal maturation, and 3) increased sensitivity to environmental stressors. Recent studies also have confirmed that EDCs have carcinogenic and mutagenic potential. In essence, these changes in physiological and biochemical parameters reflect, to some extent, some phenotypic characteristics of the deterioration of aquatic biodiversity. At present, evidence at the molecular level shows that exposure to EDCs can trigger genotoxicity, such as DNA damage, and can reduce genetic diversity. Field studies have also provided more direct evidence that EDCs contribute to the population decrease and biodiversity decline. Evolutionary toxicology and multigenerational toxicity tests have further demonstrated that EDCs can damage an organism's offspring and eventually likely lead to loss of evolutionary potential. Taken together, these results provide some basis for understanding the relationship between variety deterioration and EDC exposure. It is conceivable that there is a causal association between EDC exposure and variety deterioration of aquatic organisms. Integr Environ Assess Manag 2010;6:492–498. © 2010 SETAC
📜 SIMILAR VOLUMES
## Abstract β‐Adrenergic blockers or β‐blockers have been used therapeutically to treat human hypertension since the late 1960s. The global market value and prescription rates of β‐blockers keep rising substantially each year, and over the past decade the number of prescriptions has doubled. The wi